Novartis CAR-T cell therapy Kymriah is approved by Health Canada for 2 B-cell malignancies
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, the CAR-T cell therapy Kymriah (CTL019), developed by SwissPharmaceutical(http://giant Novartis, has been approved by Health Canada for 2 Types of B-cell malignancies :(1) B-cell acute lymphoblastic leukemia (B-ALL) children and young adults aged 3-25 years; The approval marks the beginning of a new era of cancer treatment, making Kymriah the first CAR-T cell therapy approved in Canada, Novartis is currently in talks with cancer care in Ontario, Canada, and after reaching an agreement, Kymriah will provide to young B-ALL patients who have adifficult condition to treat or who have received an allogeneic stem cell transplant (SCT) or who do not meet SCT, or have had two or more relapses;(2) adult patients with recurrent or refractory large B-cell lymphoma (R/R LBCL) who have previously received 2 or more systemic therapies, including diffuse large B-cell lymphoma (DLBCL), plifying lactator lymphoma (FL) and high-level B-cell lymphoma and DLBCLso far, two CAR-T cell therapies have been approved for the market: Novartis's Kymriah and Gilead's YescartaUnlike conventional small molecule sorority or biotherapy, it is a live T-cell therapyproduct(http://Kymriah and Yescarta are both genetically modified and genetically modified of the patient's T cells to express a chimeric antigen receptor (CAR) designed to target antigen CD19, an antigen protein that is expressed on the surface of a variety of blood tumor cells, including B-cell lymphoma and leukemia cells
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
